When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
Quibim’s AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions authorized for use in US, EU & UK
Product significantly improves patient outcomes by enabling earlier diagnosis
21 December 2023, New York / Valencia / Cambridge – Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based software to identify early-stage neurodegenerative diseases, is pleased to announce today the launch of QP-Brain®. This follows the product receiving an FDA 510(k) clearance from the US Food and Drug Administration, a CE mark for the European Union and a UKCA mark for the United Kingdom. This means the product is now cleared to be used by clinicians in those markets.
With up to one billion individuals affected by neurological diseases worldwide, plus global increases in the number of people reaching an older age when neuro-diseases are more common, the demand for quantitative assessments to detect early-stage changes in the brain has never been higher.
Currently, the vast majority of disease detection in this field comes from qualitative analysis from radiologists and neurologists. This solely human-based approach means that neuro diseases are often only detected in their later stages. In order to resolve the issue, healthcare institutions require advanced and versatile quantitative AI-based tools that can also provide secure transfer and storage of patients’ data and augment the workflow of clinicians.
QP-Brain® was therefore designed by Quibim to facilitate quantitative analysis of patients’ brains by using an AI-based tool that automatically quantifies and displays results based on the data from MRI Scans directly in PACS. The technology measures brain regions to detect subtle alterations and provides quantitative information to healthcare professionals which, in turn, optimizes the process of radiological reporting.
Additionally, Quibim’s new product provides quantification and visualization of imaging findings. This is useful for identifying patterns of brain atrophy and neurodegenerative diseases like Alzheimer’s, multiple sclerosis, and vascular and frontotemporal dementia, at earlier stages and also makes reporting more effective.
Designed with data safety in mind, QP-Brain® is compliant with both the EU General Data Protection Regulation (GDPR) and the US Health Insurance Portability and Accountability Act (HIPAA). It offers hospitals a secure way of processing and analyzing patient data and can be easily installed on a hospital server behind firewalls through a secure cloud architecture.
Dr. Angel Alberich Bayarri, Quibim’s founder and CEO, commented: “Receiving regulatory clearance for QP-Brain® in the US, EU and UK is a huge milestone for Quibim and for the early-stage detection of neurological diseases. At Quibim our mission is to develop AI technology that augments the essential role played by human medical experts to improve patient outcomes, by detecting neurological diseases and cancers much earlier than is currently possible.”
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 150+ sites are using Quibim products globally.
Contact information
